You are here

Cancer Res DOI:10.1158/0008-5472.CAN-22-0432

High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities.

Publication TypeJournal Article
Year of Publication2022
AuthorsRoh, W, Geffen, Y, Cha, H, Miller, M, Anand, S, Kim, J, Heiman, DI, Gainor, JF, Laird, PW, Cherniack, AD, Ock, C-Y, Lee, S-H, Getz, G
JournalCancer Res
Date Published2022 Aug 30
ISSN1538-7445
Abstract

Lung adenocarcinoma (LUAD) is one of the most common cancer types and has various treatment options. Better biomarkers to predict therapeutic response are needed to guide choice of treatment modality and improve precision medicine. Here we utilized a consensus hierarchical clustering approach on 509 LUAD cases from The Cancer Genome Atlas (TCGA) to identify five robust LUAD expression subtypes. Genomic and proteomic data from patient samples and cell lines was then integrated to help define biomarkers of response to targeted therapies and immunotherapies. This approach defined subtypes with unique proteogenomic and dependency profiles. Subtype 4 (S4)-associated cell lines exhibited specific vulnerability to loss of CDK6 and CDK6-cyclin D3 complex gene (CCND3). S3 was characterized by dependency on CDK4, immune-related expression patterns, and altered MET signaling. Experimental validation showed that S3-associated cell lines responded to MET inhibitors, leading to increased expression of PD-L1. In an independent real-world patient dataset, patients with S3 tumors were enriched with responders to immune checkpoint blockade (ICB). Genomic features in S3 and S4 were further identified as biomarkers for enabling clinical diagnosis of these subtypes. Overall, our consensus hierarchical clustering approach identified robust tumor expression subtypes, and our subsequent integrative analysis of genomics, proteomics, and CRISPR screening data revealed subtype-specific biology and vulnerabilities. These lung adenocarcinoma expression subtypes and their biomarkers could help identify patients likely to respond to CDK4/6, MET, or PD-L1 inhibitors, potentially improving patient outcome.

DOI10.1158/0008-5472.CAN-22-0432
Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36040373?dopt=Abstract

Alternate JournalCancer Res
PubMed ID36040373